Camlin Fine Sciences Share Price
Sector: Chemical Manufacturing
192.35 -1.95 (-1.00%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
192.00
Today’s High
197.00
52 Week Low
78.15
52 Week High
204.85
192.77 -1.61 (-0.83%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
192.00
Today’s High
197.15
52 Week Low
78.11
52 Week High
204.94
Key Metrics
- Market Cap (In Cr) 3614.66
- Beta 1.52
- Div. Yield (%) 0
- P/B 3.85
- TTM P/E -
- Peg Ratio -
- Sector P/E 17.01
- Open Price 195.5
- Prev Close 194.3
Camlin Fine Sciences Analysis
Price Analysis
-
1 Week9.82%
-
3 Months38.24%
-
6 Month63.55%
-
YTD51.88%
-
1 Year98.95%
Risk Meter
- 61% Low risk
- 61% Moderate risk
- 61% Balanced Risk
- 61% High risk
- 61% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 0.00
- 0.00
- 0.00
- 0.00
- Buy
- 2
- 2
- 2
- 1
- Hold
- 0.00
- 0.00
- 0.00
- 1
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 2
- 2
- 2
- 2
Camlin Fine Sciences News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 13 Mar 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 06 Mar 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 25 Feb 2025Camlin Fine Sciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1613.06
- Selling/ General/ Admin Expenses Total
- 408.44
- Depreciation/ Amortization
- 78.61
- Other Operating Expenses Total
- 9.44
- Total Operating Expense
- 1627.95
- Operating Income
- -14.88
- Net Income Before Taxes
- -99.24
- Net Income
- -92.75
- Diluted Normalized EPS
- -3.54
- Period
- 2024
- Total Assets
- 1951.72
- Total Liabilities
- 1086.97
- Total Equity
- 864.75
- Tangible Book Valueper Share Common Eq
- 46.96
- Period
- 2024
- Cashfrom Operating Activities
- 138.98
- Cashfrom Investing Activities
- -66.5
- Cashfrom Financing Activities
- -85.97
- Net Changein Cash
- -13.49
- Period
- 2023
- Total Revenue
- 1681.56
- Selling/ General/ Admin Expenses Total
- 390.76
- Depreciation/ Amortization
- 62.51
- Other Operating Expenses Total
- 20.49
- Total Operating Expense
- 1540.58
- Operating Income
- 140.98
- Net Income Before Taxes
- 80.38
- Net Income
- 52.11
- Diluted Normalized EPS
- 3.64
- Period
- 2023
- Total Assets
- 2060.1
- Total Liabilities
- 1240.72
- Total Equity
- 819.37
- Tangible Book Valueper Share Common Eq
- 46.84
- Period
- 2023
- Cashfrom Operating Activities
- 50.9
- Cashfrom Investing Activities
- -124.63
- Cashfrom Financing Activities
- 59.66
- Net Changein Cash
- -14.07
- Period
- 2022
- Total Revenue
- 1412.09
- Selling/ General/ Admin Expenses Total
- 339.6
- Depreciation/ Amortization
- 55.96
- Other Operating Expenses Total
- 18.52
- Total Operating Expense
- 1314.56
- Operating Income
- 97.53
- Net Income Before Taxes
- 93.98
- Net Income
- 60.68
- Diluted Normalized EPS
- 4.46
- Period
- 2022
- Total Assets
- 1800.08
- Total Liabilities
- 1052.15
- Total Equity
- 747.93
- Tangible Book Valueper Share Common Eq
- 41.82
- Period
- 2022
- Cashfrom Operating Activities
- 145.45
- Cashfrom Investing Activities
- -249.13
- Cashfrom Financing Activities
- 135.97
- Net Changein Cash
- 32.29
- Period
- 2021
- Total Revenue
- 1187.1
- Selling/ General/ Admin Expenses Total
- 278.64
- Depreciation/ Amortization
- 44.29
- Other Operating Expenses Total
- 19.47
- Total Operating Expense
- 1034.58
- Operating Income
- 152.52
- Net Income Before Taxes
- 105.1
- Net Income
- 50.96
- Diluted Normalized EPS
- 3.6
- Period
- 2021
- Total Assets
- 1481.6
- Total Liabilities
- 838.2
- Total Equity
- 643.4
- Tangible Book Valueper Share Common Eq
- 44.05
- Period
- 2021
- Cashfrom Operating Activities
- 117.38
- Cashfrom Investing Activities
- -132.86
- Cashfrom Financing Activities
- 38.63
- Net Changein Cash
- 23.15
- Period
- 2020
- Total Revenue
- 1049.15
- Selling/ General/ Admin Expenses Total
- 241.04
- Depreciation/ Amortization
- 32.8
- Other Operating Expenses Total
- 43.52
- Total Operating Expense
- 951.25
- Operating Income
- 97.9
- Net Income Before Taxes
- 58.2
- Net Income
- 30.32
- Diluted Normalized EPS
- 2.44
- Period
- 2020
- Total Assets
- 1234.06
- Total Liabilities
- 830.93
- Total Equity
- 403.14
- Tangible Book Valueper Share Common Eq
- 26.9
- Period
- 2020
- Cashfrom Operating Activities
- 86.02
- Cashfrom Investing Activities
- -90.12
- Cashfrom Financing Activities
- 3.25
- Net Changein Cash
- -0.85
- Period
- 2019
- Total Revenue
- 892.17
- Selling/ General/ Admin Expenses Total
- 220
- Depreciation/ Amortization
- 28.99
- Other Operating Expenses Total
- 30.99
- Total Operating Expense
- 851.49
- Operating Income
- 40.67
- Net Income Before Taxes
- 16.69
- Net Income
- 0.58
- Diluted Normalized EPS
- 0.04
- Period
- 2019
- Total Assets
- 1086.79
- Total Liabilities
- 715.91
- Total Equity
- 370.88
- Tangible Book Valueper Share Common Eq
- 24.52
- Period
- 2019
- Cashfrom Operating Activities
- -9
- Cashfrom Investing Activities
- -1.94
- Cashfrom Financing Activities
- 25.67
- Net Changein Cash
- 14.74
- Period
- 2024-12-31
- Total Revenue
- 433.49
- Selling/ General/ Admin Expenses Total
- 51.96
- Depreciation/ Amortization
- 14.48
- Other Operating Expenses Total
- 120.82
- Total Operating Expense
- 403.58
- Operating Income
- 29.91
- Net Income Before Taxes
- 1.52
- Net Income
- -4.14
- Diluted Normalized EPS
- -0.23
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 422.97
- Selling/ General/ Admin Expenses Total
- 52.28
- Depreciation/ Amortization
- 20.69
- Other Operating Expenses Total
- 97.94
- Total Operating Expense
- 541.02
- Operating Income
- -118.05
- Net Income Before Taxes
- -142.81
- Net Income
- -100.23
- Diluted Normalized EPS
- -0.12
- Period
- 2024-09-30
- Total Assets
- 1885.17
- Total Liabilities
- 1195.4
- Total Equity
- 689.76
- Tangible Book Valueper Share Common Eq
- 34.77
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 65.6
- Cashfrom Investing Activities
- -24.26
- Cashfrom Financing Activities
- -42.1
- Net Changein Cash
- -0.76
- Period
- 2024-06-30
- Total Revenue
- 395.85
- Selling/ General/ Admin Expenses Total
- 51.18
- Depreciation/ Amortization
- 20.11
- Other Operating Expenses Total
- 98.23
- Total Operating Expense
- 387.55
- Operating Income
- 8.3
- Net Income Before Taxes
- -23.48
- Net Income
- -33.95
- Diluted Normalized EPS
- -1.98
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 401.69
- Selling/ General/ Admin Expenses Total
- 46.17
- Depreciation/ Amortization
- 20.05
- Other Operating Expenses Total
- 89.42
- Total Operating Expense
- 467.07
- Operating Income
- -65.38
- Net Income Before Taxes
- -93.51
- Net Income
- -77.14
- Diluted Normalized EPS
- -2.62
- Period
- 2024-03-31
- Total Assets
- 1951.72
- Total Liabilities
- 1086.97
- Total Equity
- 864.75
- Tangible Book Valueper Share Common Eq
- 46.96
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 138.98
- Cashfrom Investing Activities
- -66.5
- Cashfrom Financing Activities
- -85.97
- Net Changein Cash
- -13.49
- Period
- 2023-12-31
- Total Revenue
- 385.89
- Selling/ General/ Admin Expenses Total
- 45.49
- Depreciation/ Amortization
- 20.58
- Other Operating Expenses Total
- 95.26
- Total Operating Expense
- 373.92
- Operating Income
- 11.96
- Net Income Before Taxes
- -9.73
- Net Income
- -11.79
- Diluted Normalized EPS
- -0.69
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Camlin Fine Sciences Technical
Moving Average
SMA
- 5 Day190.05
- 10 Day175.18
- 20 Day170.54
- 50 Day166.54
- 100 Day150.27
- 300 Day128.58
Camlin Fine Sciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Grauer & Weil (india)
- 84.53
- 2.22
- 2.7
- 120
- 72.16
- 3814.12
- Rossari Biotech
- 656.7
- -7.1
- -1.07
- 966
- 568.05
- 3639.13
- Camlin Fine Sciences
- 192.35
- -1.95
- -1
- 204.85
- 78.15
- 3614.66
- Kiri Industries
- 663
- -15.6
- -2.3
- 718.75
- 280
- 3646.32
- Vishnu Chemicals
- 494.55
- 7.2
- 1.48
- 562
- 282.4
- 3329.07
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Grauer & Weil (india)
- 26.75
- 4.86
- 17.09
- 11.93
- Rossari Biotech
- 28.32
- 3.26
- 14.11
- 7.12
- Camlin Fine Sciences
- -
- 3.96
- 3.14
- 1.3
- Kiri Industries
- 25.68
- 1.21
- 10.87
- 22.22
- Vishnu Chemicals
- 25.37
- 3.54
- 22.52
- 8.28
Camlin Fine Sciences Shareholding
Shareholding Pattern
*Promoter pledging: 5.32%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 23-May-25
- Audited Results
- 14-Feb-25
- Quarterly Results
- 02-Jan-25
- Others
- 22-Nov-24
- Rights issue of Equity Shares
- 11-Nov-24
- Quarterly Results
- 12-Aug-24
- Quarterly Results
- 20-May-24
- Audited Results
- 09-Feb-24
- Quarterly Results
- 06-Nov-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 25-Apr-25
- 24-Mar-25
- POM
- 20-Oct-24
- 18-Sept-24
- POM
- 31-Jul-24
- 21-May-24
- AGM
- 31-Jul-23
- 23-May-23
- AGM
- 29-Jul-22
- 19-May-22
- AGM
- 28-Mar-22
- 24-Feb-22
- POM
- 20-Jul-21
- 28-May-21
- AGM



- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 22-Nov-24
- 08-Jan-25
- 08-Jan-25
- 5:41
- 1
- 109
- Rights issue of equity shares of Re. 1/- in the ratio of 5:41 @ premium of Rs. 109/-.